Parkinson's Disease

US Patent 6630507 B1, Oct 7, 2003 - Cannabinoids as Antioxidants and Neuroprotectants

​

Study: Inhaled Cannabis Mitigates Parkinson’s Disease Symptoms

Armentano, Paul

NORML. 2014 Mar 17, online article.

​

Smoking Pot Eases Tremors in Parkinson’s

Susman, Ed.

Medpage Today. 2013 Jun 18, online article.

​

Parkinson’s Helped By Marijuana-Like Chemicals in Brain

Baker, Mitzi

Medical News Today. 2007 Feb 11, online article.

​

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease

Di Marzo, Vincenzo, et al.

The Journal of the Federation of American Societies for Experimental Biology. 2000 July, 14(10): 1432-1438 (Full).

​

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkison disease: an open-label observational study

Lotan, Treves Ta, et al.

Clinical Neuropharmacology. 2014 Mar, 37(2): 41-44 (abstract).

​

Cannabinoids and Parkinson’s Disease

Garcia-Arencibia, Moises, et al.

CNS & Neurological Disorders - Drug Targets. 2009 Dec, 8(6): 432-439 (abstract).

​

Cannabidiol for the treatment of psychosis in Parkinson’s disease

Zuardi, AW, et al.

Journal of Psychopharmacology. 2008 Sep 18, online article (abstract). 

​

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson’s disease

Lastres-Becker, Isabel, et al.

Neurobiology of Disease. 2005 Jul, 19(1-2): 96-107 (abstract).

​

Therapeutic Potential of Cannabinoids in CNS Disease

Ludovic, Dr J Croxford, et al.

CNS Drugs. 2003 Mar, 17(3): 179-202 (abstract).

​

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson’s disease

Fox, Susan H., et al.

Movement Disorders. 2002 Dec, 17(6): 1180-1187 (abstract).

​

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study

Sieradzan, K.A., et al.

Neurology. 2001 Dec 11, 57(11): 2108-2111 (abstract).

​

Neuroprotection by delta9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity

van der Stelt, M., et al.

The Journal of Neuroscience. 2001 Sep 1, 21(17): 6475-6479 (abstract).

​

The role of Cannabinoids in neurodegenerative diseases

Glass, Michelle

Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2001 May, 25(4): 743-765 (abstract).

​

Role of the endogenous cannabinoid system as a modulator of dopamine transmission: Implications for Parkinson’s disease and schizophrenia

Rodriguez de Fonseca, Fernando, et al.

Neurotoxicity Research. 2001 Jan, 3(1): 23-35 (abstract).

​

Cannabis in Movement Disorders

Muller-Vahl, K.R., et al.

Research in Complementary Medicine. 1999 Oct, 6: 23-27 (abstract).